Phase II of Radiochemotherapy in Elderly Patients With Oesophagus Cancer
Overview
- Phase
- Phase 2
- Intervention
- Cisplatin
- Conditions
- Esophagus Cancer
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Enrollment
- 23
- Primary Endpoint
- Feasibility of treatment: Number of patients with completed treatment
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Phase II study of radiochemotherapy for elderly patients with oesophagus cancer.
Detailed Description
Phase II study of radiochemotherapy for elderly patients with oesophagus cancer with Radiotherapy = 50 Gy, 2Gy/f ans chemotherapy with 2 arms arm Cisplatin = Cisplatin 75mg/m2 J1J22 or arm Oxaliplatine = oxaliplatine 85mg/m2 every 2 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients aged 75 or more with oesophagus cancer (squamous or adenocarcinoma), fit to treat
Exclusion Criteria
- •previous radiotherapy
- •no fit to treat
Arms & Interventions
Arm Cisplatin
Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
Intervention: Cisplatin
Arm Oxaliplatin
Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
Intervention: Oxaliplatin
Outcomes
Primary Outcomes
Feasibility of treatment: Number of patients with completed treatment
Time Frame: 6 weeks after end of the radiochemotherapy
number of patient with completed treatment
Secondary Outcomes
- Tumoral response(6 weeks after end of the radiochemotherapy)
- Quality of life(6 weeks after end of the radiochemotherapy)